经心尖导管主动脉瓣置换术治疗主动脉瓣反流的多中心前瞻性试验
本研究评估了新型自膨胀生物瓣膜(Ken-Valve)经心尖TAVR治疗纯主动脉瓣反流或反流合并狭窄患者的安全性和有效性。纳入142例症状性高危或不适合手术患者,1年全因死亡率为5.6%,技术成功率达97.2%,术后血流动力学和临床症状显著改善,纯AR与AR+AS患者结局无显著差异。
要点
- 经心尖TAVR使用Ken-Valve治疗纯AR或AR+AS技术成功率97.2%,1年全因死亡率5.6%。
- 术后1年平均跨瓣压差9.4±5.4 mmHg,有效瓣口面积1.9±0.6 cm2,临床症状和左室重构显著改善。
- 纯AR与AR+AS患者在死亡、并发症和血流动力学方面1年结局无显著差异。
核心结论
- 经心尖TAVR使用Ken-Valve治疗纯AR或混合AR+AS患者在中期的安全性和有效性良好。
研究设计与样本
- 多中心前瞻性试验,2021至2022年中国15家医院纳入142例症状性患者,平均年龄70.3±5.5岁,纯AR 109例,AR+AS 33例。
- 所有患者经心脏团队评估为高危或不适合手术,平均STS评分5.9±3.0%,99.3%为NYHA III/IV级。
主要发现
- 技术成功率达97.2%,2例(1.4%)因解剖不合适或瓣膜移位中转开胸。
- 新植入永久起搏器20例(14.1%),卒中3例(2.1%),大出血3例(2.1%)。
- 术后1年平均跨瓣压差9.4±5.4 mmHg,有效瓣口面积1.9±0.6 cm2。
- 截至1年,临床症状、左室重构和生活质量显著改善,纯AR与AR+AS患者结局无显著差异。
关键数值与推荐
- 技术成功定义为97.2%的病例成功完成手术。
- 术后1年平均主动脉瓣压差为9.4±5.4 mmHg,有效瓣口面积为1.9±0.6 cm2。
临床怎么用
- 对于高危或不适合手术的纯AR或AR+AS患者,经心尖TAVR使用Ken-Valve可作为治疗选择。
- 术后需关注永久起搏器植入(14.1%)、卒中(2.1%)和大出血(2.1%)等并发症。
- 术后1年随访显示血流动力学和临床症状持续改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated the safety and efficacy of transcatheter aortic valve replacement (TAVR) up to 1-year follow-up for patients with severe pure aortic valve regurgitation (AR) or mixed severe aortic valve regurgitation and aortic valve stenosis (AR+AS) using a novel self-expandable bioprosthesis. METHODS: From 2021 to 2022, transapical TAVR using Ken-Valve (Jenscare Biotechnology Ltd, Ningbo, China) was performed in 142 symptomatic patients (mean age 70.3 ± 5.5 years) with pure AR (n = 109) or AR+AS (n = 33) across 15 hospitals in China. All patients were considered high-risk or inoperable after heart team evaluation, with a mean Society of Thoracic Surgeons score of 5.9 ± 3.0%, and 99.3% in NYHA class III/IV. Procedural characteristics, echocardiography data, and clinical outcomes up to 1-year were analysed. RESULTS: Technical success was achieved in 97.2% of cases. Two (1.4%) patients were converted to open surgery due to unsuitable anatomy or valve migration during the procedure. New permanent pacemakers were implanted in 20 (14.1%) patients. Three (2.1%) patients had stroke, and 3 (2.1%) patients had major bleeding. Thirty-day mortality was 2.1%, and all-cause mortality at 1-year was 5.6% (8/142). Mean aortic valve gradient and effective orifice area (EOA) at 1-year postoperatively were 9.4 ± 5.4 mmHg and 1.9 ± 0.6 cm2, respectively. Significant improvement in clinical symptoms, positive left ventricular remodelling, and quality of life were observed up to 1-year. There was no significant difference in mortality, complications, and haemodynamic performance between patients with pure AR and AR+AS at 1-year. CONCLUSIONS: TAVR using the Ken-Valve was safe and effective in patients with pure AR or mixed AR+AS in mid-term. CLINICAL REGISTRATION NUMBER: NCT03788590.
引用
- Xiao B, Li M, Liu L, et al. Transapical Transcatheter Valve Implantation for Aortic Regurgitation: A Multicentre, Prospective Trial. Eur J Cardiothorac Surg. 2026. PMID: 42087322. doi:10.1093/ejcts/ezag065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。